Biovica’s VISION- ‘best-possible-treatment’ from day one
We envisage a future where every patient receives the best possible therapy from the very first day of treatment. Where medical decisions are tailored to individual needs rather than practices that work for some but not for others. Our assays will help clinicians predict and monitor response to treatment with unrivaled speed and precision. We will make best-possible-treatment evaluation a reality.
Biovica, a Swedish biotech company founded in 2009, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome. Our initial focus is breast cancer, where approximately 1600 new cases are diagnosed every day in the EU and US alone. By collaborating with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies, we actively promote the growing drive towards personalized medicine. Improved patient survival plus lower healthcare costs are two anticipated and welcome outcomes.
Biovica’s clinical validation plan is supported by The European Commission and has been selected to receive funding in the Horizon 2020 phase 2 program.
Biovica’s mission – more informed treatment decisions
Biovica’s biomarker assays can guide clinicians to make more informed decisions about medical treatment and follow-up, thereby delivering the right treatment to the right patient at the right time